Intellectual Property India Publishes Patent Application for 'Egfr/C-Met Bispecific Binding Protein And Use Thereof' Filed by Sichuan Kelun-Biotech Biopharmaceutical Co. Ltd.

MUMBAI, India, March 14 -- Intellectual Property India has published a patent application (202617013256 A) filed by Sichuan Kelun-Biotech Biopharmaceutical Co. Ltd., Sichuan, China, on Feb. 6, for 'egfr/c-met bispecific binding protein and use thereof.'

Inventor(s) include Zheng, Yong; Lei, Dongmei; Zhou, Yuehua; Di, Yanshu; Yi, Shuting; Long, Hu; Luo, Shuntao; Yuan, Xiaoxi; Li, Mingxiong; Shan, Wei; Li, Senwu; Song, Hongmei; Tan, Miao; Tan, Xiangyang; and Ge, Junyou.

The application for the patent was published on March 13, under issue no. 11/2026.

According to the abstract released by the Intellectual Property India: "Related to the field of disease treatment, and provided are bispecific antibodies against EGFR and c-MET, nucleic acid molecules encoding them, and methods for preparing them. Said anti-EGFR and c-MET bispecific antibody has high specificity and high affinity for EGFR and c-MET. Also provided is the use of said bispecific antibody in the treatment and diagnosis of diseases."

The patent application was internationally filed on July 05, 2024, under International application No.PCT/CN2024/103914.

Disclaimer: Curated by HT Syndication.